Carlo Alberto Paggi

chiron is pioneering advanced in-vitro technologies, enabling pharmaceutical and biotechnology innovators to derive actionable clinical insights before conducting preclinical testing or clinical trials. Our leading technologies, Re-plate and μMass, enable applications for arthritis (osteoarthritis, rheumatoid arthritis) and oncology, respectively. With these platforms, chiron uses primary, human cells to deliver predictive, human-relevant data. Re-plate recreates human-like movement in-vitro to better recapitulate the healthy and diseased states of tissue within the synovial joint, as well as other organ systems in the body. μMass is the go-to solution for the robust creation and culturing of 3D solid-tumour aggregates, in a high-throughput platform, for use in oncology potency-assay applications. Both platforms are therapeutic-modality agnostic with additional applications in other disease areas.